Steven Michael Cernoch

Array ( [id] => 17548213 [patent_doc_number] => 20220119554 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => METHOD FOR PRODUCING A VISCOSE SOLUTION AND A VISCOSE SOLUTION PRODUCED THEREBY AND A METHOD FOR PRODUCING VISCOSE FIBER [patent_app_type] => utility [patent_app_number] => 17/432573 [patent_app_country] => US [patent_app_date] => 2020-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6217 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17432573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520459 [patent_doc_number] => 20220106308 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => ANTIBACTERIALS BASED ON MONOCYCLIC FRAGMENTS COUPLED TO AMINOPIPERIDINE NAPHTHYRIDINE SCAFFOLD [patent_app_type] => utility [patent_app_number] => 17/429669 [patent_app_country] => US [patent_app_date] => 2020-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9062 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429669 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609697 [patent_doc_number] => 20220151976 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => TARGETING LASP1, EIF4A1, EIF4B AND CXC4 WITH MODULATORS AND COMBINATIONS THEREOF FOR CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 17/431418 [patent_app_country] => US [patent_app_date] => 2020-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26706 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17431418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563229 [patent_doc_number] => 20220127378 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => ACETYLATION OF NATURAL FIBRES TO OBTAIN THE FIBROUS STRUCTURE [patent_app_type] => utility [patent_app_number] => 17/431537 [patent_app_country] => US [patent_app_date] => 2020-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3597 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17431537 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578709 [patent_doc_number] => 20220135564 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => DEUTERATED MITRAGYNINE ANALOGS AS SAFER OPIOID MODULATORS IN THE MITRAGYNINE CLASS [patent_app_type] => utility [patent_app_number] => 17/427502 [patent_app_country] => US [patent_app_date] => 2020-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25110 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17427502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503427 [patent_doc_number] => 20220096529 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN (HPBETACD) FOR USE IN THE TREATMENT OF BREAST CANCER [patent_app_type] => utility [patent_app_number] => 17/426780 [patent_app_country] => US [patent_app_date] => 2020-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11428 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17426780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482125 [patent_doc_number] => 20220089629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => AMORPHOUS SIALYLATED OLIGOSACCHARIDES [patent_app_type] => utility [patent_app_number] => 17/310039 [patent_app_country] => US [patent_app_date] => 2020-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8000 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17310039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426825 [patent_doc_number] => 20220054533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => Prebiotic Composition for Butyric Acid Bacteria [patent_app_type] => utility [patent_app_number] => 17/299106 [patent_app_country] => US [patent_app_date] => 2020-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5698 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17299106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17627167 [patent_doc_number] => 20220162182 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/418388 [patent_app_country] => US [patent_app_date] => 2019-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34056 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17418388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441810 [patent_doc_number] => 20220062315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => ANTI-HUMAN NOROVIRUS AGENT [patent_app_type] => utility [patent_app_number] => 17/417974 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10660 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17417974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17593399 [patent_doc_number] => 20220142972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => PARASITICIDAL FORMULATIONS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/417063 [patent_app_country] => US [patent_app_date] => 2019-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5326 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17417063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356854 [patent_doc_number] => 20220017650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => NOVEL PROCESS FOR THE PURIFICATION OF SUGAMMADEX SODIUM [patent_app_type] => utility [patent_app_number] => 17/312382 [patent_app_country] => US [patent_app_date] => 2019-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4650 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17472459 [patent_doc_number] => 20220079963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-17 [patent_title] => A NUTRITIONAL COMPOSITION COMPRISING 2'-FUCOSYLLACTOSE (2' FL) TO IMPROVE THE GASTROINTESTINAL BARRIER [patent_app_type] => utility [patent_app_number] => 17/416571 [patent_app_country] => US [patent_app_date] => 2019-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17416571 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17369853 [patent_doc_number] => 20220024905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => CRYSTALLINE FORM OF PROPANAMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR [patent_app_type] => utility [patent_app_number] => 17/309542 [patent_app_country] => US [patent_app_date] => 2019-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6673 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17309542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19884148 [patent_doc_number] => 12269840 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-08 [patent_title] => Process for the preparation of a cyclic dinucleotide [patent_app_type] => utility [patent_app_number] => 17/299087 [patent_app_country] => US [patent_app_date] => 2019-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4818 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 153 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17299087 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945728 [patent_doc_number] => 20220332745 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => D-PSICOSE CRYSTAL AND PREPARATION METHOD THEREFOR [patent_app_type] => utility [patent_app_number] => 17/297586 [patent_app_country] => US [patent_app_date] => 2019-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17297586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17867135 [patent_doc_number] => 20220289870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => USE OF GUAR DERIVATIVES FOR MICROORGANISMS GROWTH [patent_app_type] => utility [patent_app_number] => 17/298283 [patent_app_country] => US [patent_app_date] => 2019-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17298283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18003464 [patent_doc_number] => 20220362230 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => USE OF GLUTARIMIDE DERIVATIVE FOR OVERCOMING STEROID RESISTANCE AND TREATING DISEASES ASSOCIATED WITH ABERRANT INTERFERON GAMMA SIGNALING [patent_app_type] => utility [patent_app_number] => 17/296539 [patent_app_country] => US [patent_app_date] => 2019-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5564 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17296539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17385578 [patent_doc_number] => 20220033430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => ORALLY ACTIVE PRODRUG OF GEMCITABINE [patent_app_type] => utility [patent_app_number] => 17/296403 [patent_app_country] => US [patent_app_date] => 2019-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10977 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17296403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19700055 [patent_doc_number] => 12194054 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => Application of Chidamide in combination with R-CHOP, and drug combination [patent_app_type] => utility [patent_app_number] => 17/295494 [patent_app_country] => US [patent_app_date] => 2019-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2124 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17295494 [rel_patent_id] =>[rel_patent_doc_number] =>)